New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 9, 2014
17:02 EDTSNY, REGNRegeneron, Sanofi announce positive results from Phase 2b study of Dupilumab
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis, a serious, chronic form of eczema. All doses of dupilumab met the primary endpoint of a greater improvement in Eczema Area and Severity Index scores from baseline compared to placebo. In addition, the companies also announced that four earlier clinical studies of dupilumab in moderate-to-severe atopic dermatitis were published in the New England Journal of Medicine. Dupilumab is an investigational monoclonal antibody that blocks signaling of IL-4 and IL-13, two cytokines that play a key role in the pathogenesis of moderate-to-severe atopic dermatitis.
News For REGN;SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 7, 2015
08:36 EDTREGNPiper Jaffray conference call is cancelled
Biopharmaceuticals Analyst Schimmer, along with Dr. Diana Do, a leading clinician-scientist who specializes in the treatment of retinal conditions at the University of Nebraska, discuss the current practice dynamics and treatment of wet-AMD (age-related macular degeneration), the recent AAVL Phase 2a dataset and key points of debate and emerging treatment options in wet-AMD on an Analyst/Industry conference call to be held on July 7 at 4:30 pm.
July 6, 2015
16:34 EDTSNYRetrophin closes sale of Priority Review Voucher to Sanofi
Subscribe for More Information
June 26, 2015
05:25 EDTREGNRegeneron reports approval of Eylea by Japan
Subscribe for More Information
June 25, 2015
14:03 EDTSNYSanofi initiated with a Buy at HSBC
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use